Experimental study of cryofreezing energy applications on the ventricular myocardium using sheep hearts.

BACKGROUND: Cryofreezing energy has been utilized to abolish arrhythmogenic substrates of various kinds of tachyarrhythmias. However, systematic electrophysiological and histological investigations of cryothermia have never been performed. The aim of this study was to clarify those aspects using sheep beating hearts. METHODS: A total of eight adult sheep were utilized under total anesthesia, and a pericardial cradle was made by opening the pericardium. Eight epicardial plaque electrodes were sutured on the epicardial surface of the left ventricle 2∼3 cm apart from each other. A cryoprobe was inserted through a vent made in the left ventricular apex, and positioned so as to locate the probe tip at a site just opposite the center of the epicardial plaque electrodes. Ventricular electrograms and pacing threshold were measured during endocardial freezing. The volume of the necrotized lesion created by the cryofreezing was measured in the excised hearts after staining. RESULTS: The cryoprobe tip temperature was lowered to -50°C for 10 minutes. A significant increase in the pacing threshold and significant reduction in the ventricular electrograms were observed after endocardial freezing. The transmurality of the necrotized lesions varied depending on the situation of the cryoapplications, and the lesion depth and volume were significantly larger in the transmural lesions; however, there was no significant difference between the transmural and nontransmural lesions regarding the lesion width. CONCLUSIONS: Endocardial cryofreezing could provoke significant electrophysiological and injurious effects on the ventricular myocardium in the goat heart. Transmural cryolesions could be created when cryoprobe was appropriately applied.

Sotalol and a broken heart.

An 82-year-old woman with persistent atrial fibrillation underwent successful electrical cardioversion and was begun on sotalol. After 3 days of in-hospital observation she had only mild lengthening of the QT interval. Two weeks later in clinic, the day after her husband's unexpected death, she was noted to have profound QT interval prolongation. Although she was asymptomatic and echocardiography did not disclose regional wall motion abnormalities consistent with takotsubo cardiomyopathy, she probably had a forme fruste of stress cardiomyopathy. Following emotional trauma, a period of heightened vigilance for ventricular proarrhythmia is probably warranted in women treated with antiarrhythmic drugs that lengthen repolarization.

Implantable cardiac defibrillator lead failure or myopotential oversensing? An approach to the diagnosis of noise on lead electrograms.

The appearance of noise on electrograms (EGMs) recorded from the lead of an implantable cardioverter-defibrillator (ICD) may be owing to oversensing of myopotentials, insulation breach, conductor coil fracture, loose set screw, or electromagnetic interference from an external source. The extraneous noise may lead to inappropriate shocks or inhibition of pacing. We describe two cases of pectoral myopotentials oversensing in patients with ICD and an approach to distinguish among the various extraneous noises recorded on EGMs. A systematic approach to identify the cause of the noise is important to render an appropriate treatment, which might include simple device re-programming or require re-operation and lead revision or replacement.

Impact of changing activation sequence on bipolar electrogram amplitude for voltage mapping of left ventricular infarcts causing ventricular tachycardia.

INTRODUCTION: Wavefront direction is a determinant of bipolar electrogram amplitude that could influence identification of low amplitude regions indicating infarction or scar. METHODS: To assess the importance of activation sequence on electrogram amplitude 11 patients with prior infarction and ventricular tachycardia were studied. At 819 left ventricular sites bipolar electrograms were recorded during atrial pacing and ventricular pacing, followed by unipolar pacing with a stimulus of 10 mA at 2 ms. Sites with a pacing threshold > 10 mA were designated electrically unexcitable scar. RESULTS: Areas of low voltage (< or =1.5 mV) were present in all patients. Atrial paced and ventricular paced electrogram amplitudes were strongly correlated (r = 0.77; P < 0.0001). Changing the activation sequence (from atrial pacing to ventricular pacing) produced a > 50% change in electrogram amplitude at 28% of sites and a > 100% change at 10% of sites, but only 8% of sites had an electrogram amplitude classified as abnormal (< or =1.5 mV) with one activation sequence and normal (> 1.5 mV) with the other activation sequence. Electrically unexcitable scar (6% of sites) was associated with lower electrogram amplitude but could not be reliably identified based on electrogram amplitude alone for either activation sequence. CONCLUSION: Voltage maps created with bipolar recordings using these methods should be relatively robust depictions of abnormal ventricular regions despite variable catheter orientation and activation sequences that might be produced by different rhythms.

Catheter cryoablation of cardiac arrhythmias.

PURPOSE OF REVIEW: The purpose of the review is to provide an update on the safety and efficacy of catheter cryoablation. RECENT FINDINGS: Catheter cryoablation is a safe and clinically effective method for ablation of atrioventricular nodal reentrant supraventricular tachycardia. Although the acute procedural success rate of catheter cryoablation for this arrhythmia may be slightly lower than that reported for radiofrequency ablation, it has an excellent safety profile, with no reported instances of inadvertent atrioventricular block requiring implantation of a permanent pacemaker. Using this technology, one can perform reversible cryomapping, which helps to identify suitable ablation targets while identifying sites where cryoablation should be avoided. For patients with midseptal and parahissian accessory pathways, in whom the risk of producing inadvertent atrioventricular block is substantial, catheter cryoablation is a safe and effective alternative to radiofrequency ablation. Catheter cryoablation of common atrial flutter causes much less patient discomfort than radiofrequency ablation, with excellent acute and long-term efficacy. Catheter cryoablation also can be used to isolate the pulmonary veins during ablation of atrial fibrillation. As compared with radiofrequency ablation, the risk of acute thromboembolic complications and of pulmonary vein stenosis appears to be lower with cryoablation. SUMMARY: For many cardiac arrhythmias, catheter cryoablation is a safe and effective alternative to radiofrequency ablation. The ability to identify suitable ablation targets by reversible cryomapping is a particularly useful feature of this technology. Although the acute procedural success rate of cryoablation may not equal that of radiofrequency ablation in all circumstances, as catheter technology evolves it is likely that the efficacy of cryoablation will improve and the list of arrhythmias that can be treated with this method will expand.

Identification of the ventricular tachycardia isthmus after infarction by pace mapping.

BACKGROUND: Ventricular tachycardia (VT) isthmuses can be defined by fixed or functional block. During sinus rhythm, pace mapping near the exit of an isthmus should produce a QRS similar to that of VT. Pace mapping at sites proximal to the exit may produce a similar QRS with a longer stimulus-to-QRS interval (S-QRS). The aim of the study was to determine whether a VT isthmus could be identified and followed by pace mapping. METHODS AND RESULTS: Left ventricular pace mapping during sinus rhythm was performed at 819 sites in 11 patients with VT late after infarction, and corresponding CARTO maps were reconstructed. An isthmus site was defined by entrainment and/or VT termination by ablation. Pace-mapping data were analyzed from the identified isthmus site and from sites at progressively increasing distances from this initial isthmus site. Sites where pace mapping produced the same QRS with different S-QRS delays were identified to attempt to trace the course of the isthmus. In 11 patients, 13 confluent low-voltage infarct regions were present. In all these regions, parts of VT isthmuses were identified by pace mapping. In 11 of 13 of the identified isthmus parts, the QRS morphology of the pace map matched a VT QRS. In 10 of 11 patients, radiofrequency ablation rendered clinical VTs noninducible. Successful ablation sites were localized within an isthmus identified by pace mapping in all of these 10 patients. CONCLUSIONS: VT isthmuses can be identified and part of their course delineated by pace mapping during sinus rhythm. This method could help target isthmus sites for ablation during stable sinus rhythm.

Catheter cryoablation of supraventricular tachycardia: results of the multicenter prospective "frosty" trial.

OBJECTIVE: To study the safety, efficacy, and mapping utility of a new cryoablation catheter. BACKGROUND: The CryoCath Technologies Freezor catheter has been used successfully for cryoablation of supraventricular tachycardia (SVT), but has not been evaluated in a large clinical trial. METHODS: A multicenter clinical trial to evaluate the safety, efficacy, and cryomapping utility of this cryoablation catheter was conducted in 166 subjects. The target of ablation was the slow pathway in patients with SVT due to AV nodal reentry (AVNRT, n = 103), an accessory pathway in patients with AV reentrant SVT (AVRT, n = 51) and the AV junction in patients with atrial fibrillation (AF, n = 12). RESULTS: Acute procedural success (APS) was achieved in 83% of the overall group (95% CI, 76% to 88%). APS in the AVNRT group was 91% (98.3% CI, 82% to 97%), compared to 69% for AVRT (98.3% CI, 51% to 84%) and 67% for AF (98.3% CI, 29% to 93%), a highly significant difference (P < .001 by stepwise logistic regression). In patients with APS, long-term success after 6 months was 91% overall (95% CI, 86% to 96%) and 94% for AVNRT subjects (98.3% CI, 87% to 100%). None of the AVNRT or AVRT subjects required a permanent pacemaker. Cryomapping successfully identified ablation targets in 64% of patients in whom it was attempted. The electrophysiologic effects of cryomapping were completely reversible within minutes in 94% of such attempts. CONCLUSIONS: Catheter cryoablation of SVT is a safe alternative to RF ablation and is clinically effective in patients with AVNRT. Cryomapping can reversibly identify targets for ablation and can help minimize the risk of inadvertent AV block during ablation.

Assessment of radiofrequency ablation effect from unipolar pacing threshold.

Methods for determining if an ablation lesion has been created by RF current application are limited, but needed. This study sought to determine if a change in pacing threshold at the ablation site might be used to assess creation of an ablation lesion. Peak-to-peak amplitude of the bipolar electrogram (EGM) and the unipolar pacing threshold were determined before and after creation of RF lesions using irrigated tip (63 lesions in 11 patients) or conventional ablation catheters (33 lesions in 9 patients) in infarct scars for ablation of ventricular tachycardia. The threshold was measured during continuous pacing at a cycle length of 600 ms by a decrementing output current at a pulse width of 2 ms. The unipolar pacing threshold increased by 254 +/- 248% (from 5.7 +/- 3.5 to 15.1 +/- 6.7 mA, P<0.001) after irrigated tip ablation and by 155 +/- 144% (from 5.9 +/- 3.4 to 12.3 +/- 5.7 mA, P<0.001) after conventional ablation (P<0.05 for irrigated tip vs conventional). EGM amplitude decreased by 17 +/- 27% (from 0.39 +/- 0.32 to 0.30 +/- 0.21 mV) after irrigated tip ablation and by 16 +/- 24%(from 0.48 +/- 0.27 to 0.41 +/- 0.20 mV) after conventional ablation (irrigated tip vs conventional, P=NS). There was no correlation between the change in bipolar EGM amplitude and the pacing threshold. An increase in unipolar pacing threshold is a marker of lesion creation. In regions of infarction, the relative change in threshold produced by ablation is substantially larger than the change in bipolar electrogram amplitude. The greater increase in pacing threshold after irrigated tip ablation compared to conventional ablation suggests that the magnitude of change reflects lesion size.

Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial.

INTRODUCTION: The implantable cardioverter defibrillator (ICD) is commonly used to treat patients with documented sustained ventricular tachycardia (VT) or ventricular fibrillation (VF). Arrhythmia recurrence rates in these patients are high, but which patients will receive a therapy and the forms of arrhythmia recurrence (VT or VF) are poorly understood. METHODS AND RESULTS: The therapy delivered by the ICD was examined in 449 patients randomized to ICD therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. Events triggering ICD shocks or antitachycardia pacing (ATP) were reviewed for arrhythmia diagnosis, clinical symptoms, activity at the onset of the arrhythmia, and appropriateness and results of therapy. Both shock and ATP therapies were frequent by 2 years, with 68% of patients receiving some therapy or having an arrhythmic death. An appropriate shock was delivered in 53% of patients, and ATP was delivered in 68% of patients who had ATP activated. The first arrhythmia treated in follow-up was diagnosed as VT (63%), VF (13%), supraventricular tachycardia (18%), unknown arrhythmia (3%), or due to ICD malfunction or inappropriate sensing (3%). Acceleration of an arrhythmia by the ICD occurred in 8% of patients who received any therapy. No physical activity consistently preceded arrhythmias, nor did any single clinical factor predict the symptoms of the arrhythmia. CONCLUSION: Delivery of ICD therapy in AVID patients was common, primarily due to VT. Inappropriate ICD therapy occurred frequently. Use of ICD therapy as a surrogate endpoint for death in clinical trials should be avoided.

Comparison of arrhythmia recurrence in patients presenting with ventricular fibrillation versus ventricular tachycardia in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial.

Because many episodes of ventricular fibrillation (VF) are believed to be triggered by ventricular tachycardia (VT), patients who present with VT or VF are usually grouped together in discussions of natural history and treatment. However, there are significant differences in the clinical profiles of these 2 patient groups, and some studies have suggested differences in their response to therapy. We examined arrhythmias occurring spontaneously in 449 patients assigned to implantable cardioverter-defibrillator (ICD) therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial to determine whether patients who receive an ICD after VT have arrhythmias during follow-up that are different from patients who present with VF. ICD printouts were analyzed both by a committee blinded to the patients' original presenting arrhythmia and by the local investigator. During 31 +/- 14 months of follow-up, 2,673 therapies were reported. Patients who were enrolled in the AVID trial after an episode of VT were more likely to have an episode of VT (73.5% vs 30.1%, p <0.001), and were less likely to have an episode of VF (18.3% vs 28.0%, p = 0.013) than patients enrolled after an episode of VF. Adjustment for differences in ejection fraction, previous infarction, and beta-blocker and antiarrhythmic therapy did not appreciably change the results. Ventricular arrhythmia recurrence during follow-up is different in patients who originally present with VT than in those who originally present with VF. These findings suggest there are important differences in the electrophysiologic characteristics of these 2 patient populations.

Relationship of slow conduction detected by pace-mapping to ventricular tachycardia re-entry circuit sites after infarction.

OBJECTIVES: This study sought to characterize the relationship of conduction delays detected by pace-mapping, evident as a stimulus to QRS interval (S-QRS) delay >or=40 ms, to ventricular tachycardia (VT) re-entry circuit isthmuses defined by entrainment and ablation. BACKGROUND: Areas of slow conduction and block in old infarcts cause re-entrant VT. METHODS: In 12 patients with VT after infarction, pace-mapping was performed at 890 sites. Stimulus to QRS intervals were measured and plotted in three-dimensional reconstructions of the left ventricle. Conduction delay was defined as >or=40 ms and marked delay as >80 ms. The locations of conduction delays were compared to the locations of 14 target areas, defined as the region within a radius of 2 cm of a re-entry circuit isthmus. RESULTS: Pacing captured at 829 sites; 465 (56%) had no S-QRS delay, 364 (44%) had a delay >or=40 ms, and 127 (15%) had a delay >80 ms. Sites with delays were clustered in 14 discrete regions, 13 of which overlapped target regions. Only 1 of the 14 target regions was not related to an area of S-QRS delay. Sites with marked delays >80 ms were more often in the target (52%) than sites with delays 40 to 80 ms (29%) (p < 0.0001). CONCLUSIONS: Identification of abnormal conduction during pace-mapping can be used to focus mapping during induced VT to a discrete region of the infarct. Further study is warranted to determine if targeting regions of conduction delay may allow ablation of VT during stable sinus rhythm without mapping during VT.

Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks.

BACKGROUND: Implantable cardioverter defibrillator (ICD) use reduces mortality in patients with serious ventricular arrhythmias compared with antiarrhythmic drug (AAD) use. However, the relative impact of these therapies on self-perceived quality of life (QoL) is unknown. METHODS AND RESULTS: Three self-administered instruments were used to measure generic and disease-specific QoL in Antiarrhythmics Versus Implantable Defibrillators trial participants. Generalized linear models were used to assess the relationships between self-perceived QoL and treatment (AAD versus ICD) and adverse symptoms and ICD shocks. To minimize the impact of missing data, only patients surviving 1 year were included in the primary analyses. Baseline characteristics among QoL participants (n=905) and nonparticipants (n=111) were similar, but participants who survived 1 year (n=800) were healthier at baseline than nonsurvivors (n=105). Of the 800 patients in the primary analysis, characteristics of those randomized to AAD (n=384) versus ICD (n=416) were similar. Overall, ICD and AAD use were associated with similar alterations in QoL. The development of sporadic shocks and adverse symptoms were each associated with reduced physical functioning and mental well-being and increased concerns among ICD recipients, whereas development of adverse symptoms was associated with reduced physical functioning and increased concerns among AAD recipients. CONCLUSIONS: ICD and AAD therapy are associated with similar alterations in self-perceived QoL over 1-year follow-up. Adverse symptoms were associated with reduced self-perceived QoL in both groups, and sporadic shocks were associated with reduced QoL in ICD recipients.